يعرض 1 - 20 نتائج من 186 نتيجة بحث عن '"Boni, valentina"', وقت الاستعلام: 0.58s تنقيح النتائج
  1. 1
    Academic Journal
  2. 2
    Academic Journal
  3. 3
    Academic Journal

    المساهمون: Institut Català de la Salut, Jhaveri KL Department of Medicine, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York, and Weill Cornell Medical College, New York, New York. Bellet M Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Turner NC Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom. Loi S Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, and The Sir Peter MacCallum Department of Medical Oncology, The University of Melbourne, Parkville, Australia. Bardia A Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. Boni V START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, HM Hospitales Sanchinarro, Madrid, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    Relation: Clinical Cancer Research;30(4); https://doi.org/10.1158/1078-0432.CCR-23-1796; Jhaveri KL, Bellet M, Turner NC, Loi S, Bardia A, Boni V, et al. Phase Ia/b Study of Giredestrant ±Palbociclib and ±Luteinizing Hormone-releasing Hormone Agonists in Estrogen Receptor-positive, HER2-negative, Locally Advanced/Metastatic Breast Cancer. Clin Cancer Res. 2024 Feb 15;30(4):754–66.; https://hdl.handle.net/11351/11097

  4. 4
    Academic Journal

    المصدر: Gynecologic Oncology. 159(1)

    وصف الملف: application/pdf

  5. 5
    Conference
  6. 6
    Academic Journal
  7. 7
    Academic Journal
  8. 8
    Academic Journal
  9. 9
    Academic Journal

    المساهمون: Institut Català de la Salut, Leary A Gustave Roussy Cancer Campus, Villejuif, France. Oaknin A, Braña I Vall d′Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. IOB-Quirón, UVic-UCC, Barcelona, Spain. Trigo JM Hospital Universitario Virgen de la Victoria, Málaga, Spain. Moreno V START Madrid - FJD, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain. Delord JP Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France. Boni V NEXT Madrid, Universitary Hospital QuironSalud Madrid, Madrid, Spain. START Madrid - HM CIOCC, Hospital Madrid Norte Sanchinarro, Madrid, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    Relation: European Journal of Cancer;192; https://doi.org/10.1016/j.ejca.2023.113259; Leary A, Oaknin A, Trigo JM, Moreno V, Delord JP, Boni V, et al. Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours. Eur J Cancer. 2023 Oct;192:113259.; https://hdl.handle.net/11351/10223

  10. 10
    Academic Journal
  11. 11
  12. 12
    Academic Journal

    المصدر: New England Journal of Medicine. 378(8)

    وصف الملف: application/pdf

  13. 13
  14. 14
    Academic Journal
  15. 15
    Academic Journal

    المصدر: Doz, François; van Tilburg, Cornelis M; Geoerger, Birgit; Højgaard, Martin; Øra, Ingrid; Boni, Valentina; Capra, Michael; Chisholm, Julia; Chung, Hyun Cheol; DuBois, Steven G; Gallego-Melcon, Soledad; Gerber, Nicolas U; Goto, Hiroaki; Grilley-Olson, Juneko E; Hansford, Jordan R; Hong, David S; Italiano, Antoine; Kang, Hyoung Jin; Nysom, Karsten; Thorwarth, Anne; Stefanowicz, Joanna; Tahara, Makoto; Ziegler, David S; Gavrilovic, Igor T; Norenberg, Ricarda; Dima, Laura; De La Cuesta, Esther; Laetsch, Theodore W; Drilon, Alexander; Perreault, Sebastien (2022). Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. Neuro-Oncology, 24(6):997-1007.

    مصطلحات موضوعية: Medical Clinic, 610 Medicine & health

    وصف الملف: application/pdf

    Relation: https://www.zora.uzh.ch/id/eprint/212940/1/noab274.pdf; info:pmid/34850167; urn:issn:1522-8517

  16. 16
    Academic Journal
  17. 17
    Academic Journal
  18. 18
    Academic Journal

    المساهمون: Institut Català de la Salut, Boni V START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain. Pistilli B Gustave Roussy, Villejuif, France. Braña I Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Shapiro GI Dana-Farber Cancer Institute, Boston, USA. Trigo J Hospital Universitario Virgen De La Victoria, IBIMA, Málaga, Spain. Moreno V START Madrid-FJD, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    Relation: ESMO Open;7(5); https://doi.org/10.1016/j.esmoop.2022.100571; Boni V, Pistilli B, Braña I, Shapiro GI, Trigo J, Moreno V, et al. Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study. ESMO Open. 2022 Oct;7(5):100571.; https://hdl.handle.net/11351/8428; 000861347400008

  19. 19
    Academic Journal

    المساهمون: Institut Català de la Salut, Awada AH, Aftimos P Oncology Medicine Department, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. Boni V START Madrid—HM CIOCC, Hospital Madrid Norte Sanchinarro, Madrid, Spain. Moreno V START Madrid—FJD, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain. Kahatt C, Luepke-Estefan XE PharmaMar, Colmenar Viejo, Madrid, Spain. Tabernero J Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. IOB-Quirón, UVic-UCC, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    Relation: ESMO Open;7(6); https://doi.org/10.1016/j.esmoop.2022.100651; Awada AH, Boni V, Moreno V, Aftimos P, Kahatt C, Luepke-Estefan XE, et al. Antitumor activity of lurbinectedin in combination with oral capecitabine in patients with metastatic breast cancer. ESMO Open. 2022 Dec;7(6):100651.; https://hdl.handle.net/11351/8703

  20. 20
    Academic Journal

    المساهمون: Institut Català de la Salut, Subbiah V The University of Texas MD Anderson Cancer Center, Houston, Texas. Braña I Vall d’Hebron Hospital Universitari, Barcelona, Spain. Longhi A Istituti Ortopedici Rizzoli, Bologna, Italy. Boni V START Madrid–Centro Integral Oncologico Clara Campal, Hospital Universitario Madrid Sanchinarro, Madrid, Spain. Delord JP Institut Claudius Regaud, Toulouse, France. Awada A Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    Relation: Clinical Cancer Research;28(13); https://doi.org/10.1158/1078-0432.CCR-22-0696; Subbiah V, Braña I, Longhi A, Boni V, Delord JP, Awada A, et al. Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Relapsed Ewing Sarcoma: Results of a Basket Phase II StudyAntitumor activity of lurbinectedin in relapsed ES. Clin Cancer Res. 2022 Jul 1;28(13):2762–70.; https://hdl.handle.net/11351/8089; 000823311900001